Search
Alpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. … Alpelisib was granted FDA approval on 24 May 2019.
Categories: Heterocyclic Compounds, 1-RingProducts: PİMREVA 200 MG FİLM KAPLI TABLET, 14 ADET, PİMREVA 200 MG FİLM KAPLI TABLET, 28 ADETRisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigationalRisankizumab is a fully humanized IgG1 monoclonal antibody (mAb) directed against interleukin 23 (IL-23).
Categories: Interleukin-23 Antagonist, Interleukin-23 Subunit p19Products: Skyrizi 150 mg/ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Kalem, 1 ADET, SKYRİZİ 150 MG/ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETErenumab
go.drugbank.com/drugs/DB14039ApprovedInvestigationalIt is composed of 2 heavy chains, each containing 456 amino acids, and 2 light chains of the lambda subclass, each containing 216 amino acids, with an approximate molecular weight of 150 kDa [FDA Label … Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines
Products: AIMOVIG (70 MG/ML SOLUTION FOR INJECTION), KUZELVA 70 MG ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETSelegiline
go.drugbank.com/drugs/DB01037ApprovedInvestigationalVet approvedA selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may...
Products: SELEGILIN-NEURAX 10 MG, SELEGILIN AL 10Cobimetinib
go.drugbank.com/drugs/DB05239ApprovedInvestigationalCobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction … It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
Categories: Heterocyclic Compounds, 1-Ring, MAP Kinase Kinase 1, antagonists & inhibitorsProducts: COTELLIC FILM-COATED TABLET 20 MG, COTELLIC® (COBIMETINIB) 20 MG TABLETAS RECUBIERTASHydroxychloroquine
go.drugbank.com/drugs/DB01611ApprovedInvestigational[A192132] **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020. … [L14312]** Hydroxychloroquine was granted FDA approval on 18 April 1955.[L8072] A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19.[A192546]
Categories: Heterocyclic Compounds, 2-RingSynonyms: 7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline, 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinolineTemsirolimus
go.drugbank.com/drugs/DB06287ApprovedInvestigationalIt was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Products: TORISEL 25 MG/ML IV INFUZYONLUK COZELTI ICEREN FLAKON, 1 ADET, TORISEL ® 30 MGCONCENTRADO PARA SOLUCION PARA INYECCION(25 MG/ML)Clonidine
go.drugbank.com/drugs/DB00575ApprovedInvestigationalClonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors.[A180559] This activity is useful for the treatment of hypertension, severe pain, and ADHD. … [L7237,L54536,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974.[L7237]
Mixtures: Combipres 0.1/15 TabCategories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor AgonistsBosutinib
go.drugbank.com/drugs/DB06616ApprovedInvestigational[L48436] On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. … [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving
Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrileIbutilide
go.drugbank.com/drugs/DB00308ApprovedIbutilide is a Class III antiarrhythmic agent available in intravenous formulations. It is indicated for the conversion of acute atrial flutter and recent onset atrial fibrillation to normal sinus rhythm (NSR).
Synonyms: N-(4-{4-[ethyl(heptyl)amino]-1-hydroxybutyl}phenyl)methanesulfonamideProducts: Fybrio 1 mg/10 ml I.V. Enjeksiyonluk Çözelti, 1 ADET, Corvert 87 Mikrogramm/ml Infusionslösung